Symbol="ALVR"
AssetType="Common Stock"
Name="AllovirÂ Inc"
Description="Allovir, Inc., a clinical-stage cell therapy company, is dedicated to the research and development of ready-to-use, multi-virus-specific allogeneic T-cell therapies (TSVs) to prevent and treat devastating virus-associated diseases. The company is headquartered in Cambridge, Massachusetts."
CIK="1754068"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="139 MAIN STREET, SUITE 500, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="353259000"
EBITDA="-173578000"
PERatio="None"
PEGRatio="None"
BookValue="2.079"
DividendPerShare="0"
DividendYield="0"
EPS="-1.78"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.45"
ReturnOnEquityTTM="-0.861"
RevenueTTM="0"
GrossProfitTTM="165000"
DilutedEPSTTM="-1.78"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="21.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="2.465"
EVToRevenue="-"
EVToEBITDA="-2.054"
Beta="0.636"
num_52WeekHigh="10.29"
num_52WeekLow="2.85"
num_50DayMovingAverage="3.861"
num_200DayMovingAverage="5.22"
SharesOutstanding="113588000"
DividendDate="None"
ExDividendDate="None"
symbol="ALVR"
open="2.96"
high="3.05"
low="2.86"
price="3.03"
volume="252534.00"
latest_trading_day="2023-08-08"
previous_close="2.95"
change="0.08"
change_percent="2.7119%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="89"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="11"
Volume_recent_avg="511039"
Change_recent_avg="0.01"
Delta_recent_avg="0.36"
Variance_recent_avg="0.18"
Change_ratio_recent_avg="-0.3"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="11"
Aroon_momentum_negative="89"
image_negative_thumbnail_id_1="141"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0035.jpeg"
image_negative_thumbnail_id_2="111"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0065.jpeg"
image_neutral_thumbnail_id_1="540"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_neutral_thumbnail_id_2="528"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0071.jpeg"
image_positive_thumbnail_id_1="979"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0141.jpeg"
image_positive_thumbnail_id_2="672"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0036.jpeg"
image_professor_thumbnail_id_1="1193"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
image_professor_thumbnail_id_2="1203"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
